Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cardiol Therapeutics Inc T.CRDL

Alternate Symbol(s):  CRDL | T.CRDL.W.A

Cardiol Therapeutics Inc. (Cardiol) is a Canada-based clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). The Company's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.


TSX:CRDL - Post by User

Post by NewFanCBDon Jun 23, 2021 6:36am
142 Views
Post# 33432890

Pretty quiet in here.

Pretty quiet in here. But not for long. The company has been fairly quiet that's for sure but don't be mistaken, this kettle is boiling and we might start to hear the whistle from it in the very near future. Lots of catalysts going on. The company has lots of cash and there's a ton of potential here. The sector is huge and when this gets to NASDAQ, there will be many more eyes on it. Bargain basement price is at this juncture.
<< Previous
Bullboard Posts
Next >>